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Abstract 
 
The chimeric MLL-EEN fusion protein is created as a result of chromosomal translocation 
t(11;19) (q23;p13).  EEN, an SH3 domain containing protein in the endophilin family, has 
been implicated in endocytosis, although little is known about its role in leukemogenesis 
mediated by the MLL-EEN fusion protein. In this study, we have identified and characterized 
EBP, a novel EEN binding protein that interacts with the SH3 domain of EEN through a 
proline-rich motif PPERP. EBP is a ubiquitous protein which is normally expressed in the 
cytoplasm but is recruited to the nucleus by MLL-EEN with a punctate localization pattern 
characteristic of the MLL chimeric proteins. EBP interacts simultaneously with EEN and Sos, 
a guanine-nucleotide exchange factor for Ras. Coexpressoin of EBP with EEN leads to 
suppression of Ras-induced cellular transformation and Ras-mediated activation of Elk-1.  
Taken together, our findings suggest a new mechanism for MLL-EEN-mediated 
leukaemogenesis in which MLL-EEN interferes with the Ras-suppressing activities of EBP 
through direct interaction.  
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Introduction 
 
Chromosomal translocations that disrupt the human homolog of the Drosophila 
thrithorax (TRX) gene, MLL (mixed lineage leukemia) gene at 11q23 are frequently found in 
human leukemias1-3.  TRX is a transcriptional activator required to maintain expression of 
homeotic genes during Drosophila embryonic development4,5.  Knockout studies in mice 
have shown that MLL, like TRX in Drosophila, has a similar function in mammals with 
MLL heterozygous mice showing abnormal skeletal and haemopoietic development.6,7. MLL 
encodes for a protein of 3968 amino acids with structurally complex domains. In the N 
terminus there are three AT hook motifs and a cysteine-rich region (CxxC motif), which is 
homologous to mammalian DNA methyltransferase and is responsible for DNA binding8. 
Regions of conservation between MLL and TRX are located in the internal plant 
homeodomain zinc fingers and the C terminal SET domain.  Both domains are thought to 
function in protein-protein interaction and chromatin modification9,10.   
Translocations of the MLL result in formation of chimeric proteins in which the N 
terminus of MLL is fused in-frame to the C terminus of fusion partners. There are at least 35 
MLL fusion partners identified to date – though diverse in structure and function, they can be 
classified into families or groups. A group of nuclear fusion partners, including AF4, AF9, 
AF10, ENL, ELL, AF17, AFX1, AF6q21, CBP and P300, has been implicated in various 
aspects of transcriptional regulation. The remaining group of cytoplasmic fusion partners, 
including AF6, AF1p, Abi-1, EEN and FBP17, possesses structural domains responsible for 
protein-protein interaction11.  While direct fusion with transcriptional effector domains 
resulting in aberrant transcriptional activation activities may represent a common oncogenic 
mechanism for certain MLL-nuclear fusion proteins12-18, the leukemogenic mechanisms 
mediated by MLL-cytoplasmic fusion proteins are still largely unknown.19-21.   
EEN, an SH3 domain containing gene of the endophilin family localized on 
chromosome 19p13, is fused to MLL as a result of t(11;19) chromosomal translocation in a 
case of infant acute myeloid leukemia22.  EEN and its two related family members, EEN-B1 
and EEN-B2, also known as endophilins II, I and III respectively, shared the SH3 domains 
that are closely related to the SH3 domain of the adaptor protein Grb223,24,27.  All three 
members have been reported to be binding partners of endocytic proteins, synaptojanin, 
dynamin and amphiphysins, which are implicated in the trafficking of synaptic vesicles in the 
presynaptic nerve terminal24-28 and with the G-protein-coupled β1-adrenergic receptor29.  
Unlike EEN-B1 and EEN-B2 which show restricted tissue expression mainly in the brain, 
EEN is ubiquitously expressed30.  Little is known on the function of EEN in haemopoietic 
cells and the role played by EEN in MLL-EEN mediated leukaemogenesis.  
In this study, we describe the identification of a cytoplasmic protein designated EBP 
for EEN binding protein that specifically interacts with EEN in the cytoplasm. We show that 
expression of MLL-EEN results in relocation of EBP from the cytoplasm into the nucleus to 
produce a distinct punctate pattern typical of MLL fusion proteins31,32.  Our results also show 
that EBP possesses inhibitory effect on Ras signaling and cellular transformation induced by 
Ras, a property of probable biological significance and relevance in the context of MLL-EEN 
mediated leukaemogenesis.  
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Materials and Methods 
 
Plasmid constructions 
 
Various expression constructs using pAS2-1, pGADGH, pGEX1, pFLAG.CMV2 and 
pCS2+MT were prepared by standard molecular biology techniques and polymerase chain 
reaction (PCR) amplification of the described fragments.  Gal4 DNA-binding (BD) vector, 
pAS2-1 carrying EEN with the following amino acids were made: EEN 1-368 (FL), 1-266 
(NCC), 131-368 (CCSH3), 131-266 (CC) and 303-368 (SH3), EENB1 1-352 (FL) and 
EENB2 1-347 (FL). Gal4-BD vectors of EBP fragments 1-767 (FL) and SH3 domains (A, B, 
C and D) were also constructed.  Gal4 activation domain (AD) vector, pGADGH carrying 
EBP with the following amino acids was constructed: EBP 1-767, 76-767, 94-767, 94-357, 
532-767, 272-666, 272-533, 272-358, 272-342, 348-419 and U343-347 (272-533 with 
internal 343-347 deletion).  Fragment of Sos2-C (amino acids 974-1262) was cloned into 
Gal4-AD.  Plasmids for bacterial expression of glutathione S-transferase (GST) fusion 
protein were made using pGEX1: EEN 303-368 (SH3 domain), EBP 272-358 and EBP 348-
419.  Eukaryotic expression vector, pCS2+MT of Myc-tagged proteins were prepared as 
follows: EBP 1-767, 76-767, 1-358 and 532-767, and Sos2-C (amino acids 974-1262).  
FLAG-tagged expression vector, pFLAG-CMV-2 (Sigma) carrying EEN, EEN deletion 
mutants, EENUSH3, EEN with nuclear localization signal (NLS), NLSEEN and 
NLSEENUSH3 and MLL-EEN were constructed.  
 
Yeast two-hybrid library screening and binding assay 
 
Library screening was performed by sequential transformation the yeast strain Y190 was first 
transformed with the bait, EEN1-368pAS2-1 plasmid carrying full-length EEN fused to Gal4-
BD, and subsequently with the HeLa cell cDNA library constructed in the Gal4-AD plasmid, 
pGADGH by large-scale lithium acetate transformation protocol.  The transformation 
mixture was spread on SD/-Trp/-Leu/-His plates, and isolated positive clones carrying 
potential EEN interaction proteins were assayed for β-galactosidase activity on filters.  The 
library plasmids were recovered from the positive colonies and were sequenced.  To test the 
interacting potential between two known proteins, yeast strain SFY562 were co-transformed 
with Gal4-BD and Gal4-AD constructs carrying the potential interacting proteins.  
Transformation mixtures were spread on plates with SD/-Trp/-Leu for selection of 
cotransformants and qualitative colony-lift filter assay was performed.  For the quantitative 
interaction assay, the cotransformants were lysed and the β-galactosidase activity was 
quantified using the substrate o-nitrophenyl β-D-galactopyranoside (ONPG). 
 
Tissue expression study by polymerase chain reaction 
 
The expression of EBP on a panel of human multiple tissue cDNA (Clontech) was examined 
by PCR.  In each reaction, 0.2 ηg of human cDNA was amplified with 10 pmol of each EBP 
gene specific primers, EBP348F (5’-CCTCCCCCAAAGCTTTCT-3’) and EBP419R (5’-
AAGTACATCCCCACGCAT-3’).  Normalization of tissue cDNA panel was examined by 
amplification of actin. 
 
Cell culture and transfection 
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HeLa cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% (v/v) fetal bovine serum, penicillin and streptomycin at 37ºC in a humidified 
incubator with 5% CO2 in air.  Rats 6 (R6) cells33 were grown in DMEM supplemented with 
10% calf serum.  Transfection of cells was performed by standard calcium phosphate 
precipitation protocol.  Semiconfluent cells in 100 mm plate were transfected with 20 μg of 
plasmid DNA for 16 h and harvested after 48 h.  For immunofluorescence staining, cells 
seeded on coverslips in 35 mm plate were transfected by using Fugene 6 reagent according to 
the manufacturer’s instruction (Roche). 
 
Co-immunoprecipitation 
 
Transfection cells were harvested, washed with ice-cold phosphate-buffered saline (PBS), 
and lysed on ice in NETN buffer (150 mM NaCl, 5 mM EDTA, 50 mM Tris, pH 7.4, 1× 
complete protease inhibitors (Roche), 1% NP-40).  Lysed cells were cleared by centrifugation 
and supernatants were collected.  Protein concentration was determined by Bradford reagent 
(Bio-Rad).  For co-immunoprecipitation of Myc-tagged EBP and FLAG-tagged EEN, 
supernatants were incubated with anti-FLAG antibody (Sigma) overnight at 4°C, after which 
immunoprecipitates were collected with protein A-sepharose for 4 h at 4°C with constant 
rotation.  The beads were washed five times with NET lysis buffer and boiled in sample 
buffer.  The immunoprecipitates were subjected to 10% SDS-polyacrylamide gel 
electrophoresis, and the proteins were transferred to Immobilon-P membrane (Millipore).  
Western blots were probed by anti-Myc antibody (Santa Cruz Biotechnology) and 
horseradish peroxidase conjugated secondary antibody, then visualized by ECL reagents 
(Amersham Pharmacia Biotech). 
 
GST pull-down assay 
 
Glutathione S-transferase (GST) fusion proteins of EEN SH3 domain and EBP proline rich 
region were expressed in host strain BL21(DE3).  Expression of fusion proteins was induced 
upon the addition of isopropyl-β-D-thiogalactopyranoside to a final concentration of 0.1 mM 
in exponentially growing bacterial cultures at 37°C for 3 h.  Bacteria were collected and lysed, 
and fusion proteins were purified on glutathione Sepharose beads (Amersham Pharmacia 
Biotech).  Cell lysates prepared as described above were incubated with 5 μg of GST fusion 
proteins immobilized on glutathione sepharose beads for 2 h at 4°C with constant rotation.  
The beads were washed with NET buffer and bound proteins were eluted and prepared for 
Western blot analysis.  Bound proteins were detected by anti-Myc antibody.   
 
Immunofluorescent staining 
 
Cells grown on coverslips were fixed in 4% paraformaldehyde in PBS and permeabilized 
with 0.5% Triton X-100 in PBS for 10 min.  Cells were then blocked with 5% goat serum in 
PBS, and incubated with primary antibodies (rabbit anti-Myc or mouse anti-FLAG antibodies) 
for 1 h, followed by secondary antibodies (anti-rabbit fluorescein isothiocyanate (FITC)-
conjugated or anti-mouse rhodamine-conjugated) (Jackson Immunoresearch) for 45 min with 
extensive washing in between.  Cells were counterstained with DAPI (Calbiochem) and 
mounted in Vectashield antifade mountant (H1000, Vector Lab).  Images were captured by a 
fluorescence microscope equipped with CCD camera (Leica). 
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Luciferase assay 
 
HeLa cells in 24-well plates were transfected with different combinations of plasmids using 
Fugene 6 reagent.  Plasmids used included pCS2+MT-EBP, pCMV2-FLAG-EEN, pUSE-
RasQ61L (Upstate Biotech), pGal4-luc, pFA-Elk-1 reporter constructs (Stratagene) and an 
internal control pRLSV40.  Cell lysates were harvested 24 hr after transfection, prepared and 
assayed using Dual Luciferase Reporter assay system (Promega) according to the 
manufacturer’s instructions.  Each transfection was done in triplicates.  Mean values were 
calculated from triplicate wells and from three independent experiments. 
 
Soft agar assay 
 
Cells were suspended at 1×104/60 mm plate with 2 ml of 0.4% Bacto-agar in DMEM 
containing 20% fetal calf serum and overlaid above a layer of 5 ml of 1% agar in the same 
medium in triplicate plates.  At day 14, colonies were stained with the vital stain 2-(p-
iodopenyl)-3-(p-nitrophenyl)-5-phenyltetrazolium chloride hydrate for 48 h at 37°C in a 5% 
CO2 incubator, and the numbers and sizes were scored. 
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Results 
 
Identification and tissue expression of EBP 
 
To search for potential binding partners of EEN, we performed yeast two-hybrid screening of 
a HeLa cell cDNA library using the full-length EEN as bait.  Two positive clones, #30 and 
#46 had identical nucleotide sequence.  These two clones were identical to reported sequence 
DKFZp434D0215 (GI: 27477709) which encodes a hypothetical protein of 767 amino acids 
(Figure 1A).  Sequence alignment between our library-screened clones and the reported 
sequence revealed that our clones are partial clones with an incomplete N terminal.  We 
obtained the N terminal fragment by PCR using HeLa cell cDNA as template.  The full 
length cDNA for the novel interacting partner of EEN named as EBP (EEN binding protein) 
was obtained.  Structural analysis of EBP amino acid sequence revealed that it contained a 
proline rich region (PRR) from amino acids 320 to 350 followed by four SH3 domains in the 
C terminus (Figure 1A, 1B).  To determine tissue distribution of EBP, the expression of EBP 
was studied by PCR analysis on various human tissue cDNAs.  An expected amplified 
product of 213-bp was obtained and sequenced.  Similar to EEN that is ubiquitously 
expressed30, EBP was detected in all adult and fetal tissues being tested (Figure 1C).  The 
concomitant tissue distribution of EBP and EEN suggests that the two proteins are possibly to 
be binding partners in various tissues. 
 
EEN SH3 domain is the EBP-interacting domain 
 
Full-length EEN was used as bait in the yeast two-hybrid library screening.  Structurally, 
EEN comprises a central coiled coil domain and a SH3 domain in the C terminus, which are 
domains responsible for protein-protein interaction34.  In order to map the minimal EBP-
interacting domain of EEN, various EEN deletion fragments fused with the Gal4-BD in the 
pAS2-1 plasmid were co-transformed with clone #30, one of the positive clones of EBP into 
the SFY562 yeast reporter strain (Figure 2A).  Among the constructs tested, only the full-
length EEN and mutants carrying the SH3 domain showed positive interaction with EBP 
(Figure 2B, 2C).  The SH3 domain of EEN was shown to be binding domain of EBP.  The 
EBP-EEN interaction was further confirmed by an in vitro GST pull down assay.  Specific 
binding with Myc-tagged EBP was observed with the GST-EEN fusion protein containing the 
SH3 domain of EEN (GST-SH3) protein but not with the control GST protein (Figure 2D). 
 
Differential interaction of EBP with EEN family members 
 
As the sequences of the SH3 domains are highly conserved among the EEN family members, 
we therefore examined whether the other two members, EEN-B1 and EEN-B2 could also 
interact with EBP.  The colony lift filter assay showed that EBP positively interacted with 
EEN and EEN-B2, but interaction with EEN-B1 was barely detected (Figure 3A).  The 
quantitative β-galactosidase assay further demonstrated that EBP had the strongest interaction 
with EEN (Figure 3B).  Although EEN family members are known to interact with common 
proteins, for instance, synaptojanin, dynamin via the highly conserved SH3 domain30, the 
discrepancies in SH3 domains sequence identity between EEN, B1 and B2 might confer the 
binding specificity to each of the members (Figure 3C). 
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Proline rich binding motif of EBP is required for interacting with EEN 
 
Using yeast two-hybrid cotransformation assay, we showed that full-length EBP was able to 
interact with EEN (Figure 4A).  To map the interacting region of EBP for EEN, constructs 
carrying various deletion mutants of EBP fused with the Gal4-AD were constructed and co-
transformed with EEN Gal4-BD plasmid into yeast strain SFY526.  The minimal binding 
region of EEN was mapped to amino acids 342 to 358 of EBP.  Within this minimal region, a 
putative EEN-binding motif, PPERP (amino acids 343-347) is located which matches the 
consensus proline rich binding motif, PPXRP previously reported to interact with the SH3 
domain of endophilins/EEN34.  Interaction with EEN via the proline rich motif in residues 
343 to 347 was further confirmed by an internal deletion construct U343-347 which showed 
no interaction with EEN.  Specific interaction between EEN with the proline rich binding 
motif was confirmed by an in vitro GST pull down assay (Figure 4B).  In this experiment, 
Myc-tagged EEN expressed in HeLa cell lysate was pulled down by fragment of EBP (amino 
acids 272 to 358) containing the putative EEN-binding motif expressed as a GST fusion 
protein immobilized on glutathione beads.  No interaction was observed between EEN and 
another proline rich sequence, PPRPKP of EBP resides in amino acids 348 to 419 revealed 
that interaction between EEN and EBP was specifically mediated through the proline rich 
binding motif, PPERP in amino acids 343-347.  To explore the interaction of EEN and EBP 
in vivo, Myc-tagged full length EBP (1-767) and partial EBP (76-767) were transiently 
transfected with either FLAG-tagged EEN or SH3 domain deletion mutant EENUSH3 into 
HeLa cells.  Myc-tagged EBP was co-immunoprecipitated with intact FLAG-tagged EEN.  
Deletion of the SH3 domain of EEN abrogated its interaction with EBP (Figure 4C). 
 
EBP co-localizes and interacts with EEN in vivo 
 
To determine the subcellular localization of EBP, Myc-tagged EBP was transiently 
transfected into HeLa cells.  The expression of the Myc-tagged proteins in transfected cells 
was visualized by anti-Myc antibody, followed by FITC-conjugated antibody.  EBP was 
observed to be evenly distributed in the cytoplasm (Figure 5A).  The N terminal of EBP from 
amino acids 1 to 358 including the proline rich region also displayed similar cytoplasmic 
localization when transiently expressed in the HeLa cells (Figure 5B).  However, the C 
terminal of EBP from amino acids 532 to 767 consists of the last three SH3 domains showed 
localization both in the cytoplasm with a uniform pattern and also in the nucleus with a 
punctate distribution (Figure 5C).  This observation could be the result of the loss of 
structural domain, located within the N terminal domain that is responsible for retaining EBP 
in the cytoplasm. 
 To determine whether EBP and EEN share similar subcellular localization, Myc-
tagged EBP was expressed either alone or together with FLAG-tagged EEN in HeLa cells.  
Simultaneous ectopic expression of EBP and EEN in transfected cells displayed uniform 
cytoplasmic localization (Figure 5D).  To test whether EBP and EEN could interact with each 
other in vivo, a nuclear localization signal (NLS) was added to EEN that would redirect EEN 
from the cytoplasm into the nucleus.  HeLa cells transfected with Myc-tagged EBP and 
FLAG-tagged NLSEEN resulted in nuclear localization of both proteins (Figure 5E).  In 
addition, NLSEEN with a deletion in SH3 domain, the EBP binding domain, was unable to 
bring EBP into the nucleus (Figure 5F).  This observation supports direct physical interaction 
between EBP and EEN in vivo as well as a role of the SH3 domain of EEN in interacting and 
modulating the subcellular localization of EBP.  
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MLL-EEN fusion protein delocalizes EBP into the nucleus 
 
The native nuclear localization of the MLL-EEN fusion gene prompts us to study the effect 
of coexpression of EBP and MLL-EEN in cells.  In HeLa cells expressing exogenously 
introduced EBP and MLL-EEN, EBP is localized in both cytoplasm and nucleus (Figure 5G).  
MLL-EEN and EBP both exhibited a punctate localization in the nucleus, a pattern also 
reported for other MLL fusion proteins32. Our study shows that MLL-EEN could only 
partially relocate EBP into the nucleus while NLSEEN could more efficiently relocate EBP 
into the nucleus.  The difference in the ability of MLL-EEN and EEN in relocating EBP may 
be due to the significant protein size difference between the two proteins.  We postulate that 
the relatively large protein size of MLL-EEN (1715 amino acids) as compared with EEN 
(368 amino acids) might prevent access of the EBP-binding domain in EEN to EBP.  Under 
this circumstance, MLL-EEN would not be able to interact with all EBP proteins present 
inside the cells and relocate them all from the cytoplasm into the nucleus.  Our results 
demonstrate that EEN specifically interacts with EBP, and its subcellular localization as a 
MLL-EEN fusion protein can directly affect the subcellular localization of EBP. 
 
EBP interacts with EEN and Sos2 simultaneously 
 
Structural comparison of EBP with known proteins revealed that EBP is similar to intersectin, 
an endocytic protein with multiple SH3 domains in the C terminal35,36.  Moreover, Son of 
sevenless (Sos), a guanine-nucleotide exchange factor of Ras was identified as a SH3 
domain-binding partner of intersectin37,38.  To study the potential interaction between EBP 
and Sos, we performed yeast two-hybrid cotransformation assay to test the interaction 
between deletion mutants of EBP fused to Gal4-BD and the C terminal of Sos1 and Sos2 
(Sos1-C and Sos2-C) fused to Gal4-AD.  EBP was found to interact with Sos2 but not with 
Sos1 (data not shown).  Our results showed that two pairs of the consecutive SH3 domains 
(SH3 B-C and SH3 C-D) of EBP were sufficient to interact with Sos2 (Figure 6A).  The 
specific interactions between EBP SH3 domains and Sos2 were also demonstrated by the in 
vitro GST pull-down assay.  In this assay, the first two SH3 domains of EBP (SH3 A-B) were 
unable to pull down Sos2, while SH3 B-C and SH3 C-D could efficiently bind Sos2 (Figure 
6B).  By using quantitative liquid culture assay of the yeast cotransformants, the last two SH3 
domains (SH3 C-D) had the highest binding affinity to Sos2 (Figure 6C). 
 Our results show that EBP has distinct binding sites for EEN and Sos2, and EEN and 
Sos2 do not interact with each other (data not shown).  To address the question whether EBP 
is able to interact with EEN and Sos simultaneously and form a stable trimeric protein 
complex, we performed a co-immnuoprecipitation reaction followed by a GST pull-down 
assay.  Myc-tagged EBP and Sos2-C were transfected into HeLa cells and incubated with 
GST-EENSH3 fusion protein immobilized on glutathione sepharose beads.  Both Myc-tagged 
proteins could be differentiated by their significant protein size difference.  EBP-Myc protein 
could be pulled down by GST-EENSH3, and Sos2-C-Myc could only be detected when EBP-
Myc was cotransfected (Figure 6D). 
 
Expression of EBP and EEN inhibits Ras transformation potential and Ras-mediated 
activation of Elk-1 
 
Association of EBP with Sos2, a guanine exchange factor of Ras prompts us to investigate 
the effect of EBP and EEN on Ras-induced cellular transformation.  Stable transfectants of 
R6 cells expressing dominant active mutant, RasQ61L with or without EBP and/or EEN were 
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examined for anchorage-independent growth on soft agar.  Normal R6 cells remained as 
single cells while R6 cells induced by RasQ61L formed large colonies (size range: 0.05-0.68 
mm) (Figure 7A, 7B).  Cotransfection of RasQ61L with EBP and EEN showed up to 40% 
and 70% reductions in the number and size of colonies (size range: 0.05-0.27 mm).  The 
expressions of EEN and EBP in stable transfectants were detected by Western blot analysis 
(Figure 7C).  
 EBP displays high structural similarity with the multiple SH3 domains in the C 
terminal of intersectin, which reported to interact with Sos and activate Elk-1 activation39,40, 
we therefore investigate the effect of EBP on the downstream signaling of Ras by performing 
luciferase assay using Gal4-Elk-1 trans-reporter.  Expression of RasQ61L, a constitutively 
active mutant enhanced the activation of Elk-1 trans-reporter by 6-fold (Figure 7D).  When 
EBP and EEN were cotransfected with RasQ61L, activation of Elk-1 transcription factor by 
RasQ61L was reduced by 45%, and the effect of inhibition by EBP and EEN was more 
efficient than expression of either EBP or EEN alone.  However, this inhibitory effect was 
lost when NLSEEN and EBP were transfected.  Since NLSEEN interacts and relocates EBP 
into the nucleus (Figure 5E), therefore our reporter assays suggest that the inhibitory effect of 
EEN and EBP on activation of Elk-1 requires the cytoplasmic localization of both EEN and 
EBP.  The inhibition effect of EBP and EEN on the basal activity and Ras-mediated 
activation of Elk-1 occurred in a dose-dependent manner (Figure 7F).  Taken together, our 
results show that EBP and EEN cooperatively inhibit Ras signaling, and also suppress 
cellular transformation induced by Ras. 
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Discussion 
 
EEN was originally identified as a MLL fusion partner in acute myeloid leukaemia22 and 
preliminary studies based on retroviral transduction of mice haemopoietic stem cells indicates 
EEN is necessary for MLL mediated leukemogenesis (So et al., unpublished data).  To 
investigate the role of EEN in the pathogenesis of leukaemia, we have identified and 
characterized a ubiquitously expressed protein, EBP, as a novel binding partner of EEN.  
Structurally, EBP comprises an N terminal region, a central proline rich region, followed by 
four SH3 domains in the C terminal.  Fine mapping of EBP reveals a proline rich binding 
motif, PPERP (residues 343-347) which interacts with the SH3 domain of EEN and is 
consistent with the consensus endophilin binding sequence, PPXRP34. Specific and direct 
interaction between EBP and EEN was further confirmed by the in vitro GST pull-down 
assay and in vivo co-immunoprecipitation studies (Figure 4).  In spite of the high sequence 
homology of the SH3 domains among the EEN family members, the preferential interaction 
between EEN and EBP (Figure 3) further strengthens the notion that EBP is a bona fide 
interacting partner for EEN and each EEN member may have related but distinct functional 
roles in cell signaling. 
 
 Structural and functional analysis shows that EBP shares some similarity to 
intersectin, an adaptor protein with multiple SH3 domains that interacts with Son of sevenless 
(Sos), a guanine-nucleotide exchange factor and activator of Ras38.  Analogous to intersectin, 
EBP recruits Sos2 via its SH3 domains to form a stable trimeric complex with EEN mediated 
by its consensus endophilin binding sequence. Intersectin has been shown to regulate the 
Ras/MAP kinase pathway and activate Elk-1 transcription factor resulting in oncogenic 
transformation of rodent cells38-40.  Over expression of a dominant negative mutant with SH3 
domains of intersectin repressed the activation of Ras and Elk-139, and failed to induce 
transformation40.  In contrast to intersectin, the expression of EBP not only suppressed the 
transcriptional activation of Elk-1 but also Ras-induced oncogenic transformation (Figure 7) 
Moreover, coexpression of EEN significantly enhanced the inhibitory effects on Ras-
mediated transactivation and transformation (Figure 7), suggesting that the EEN-EBP-Sos 
trimeric complex likely contributes to the observed repressive effects.   Taken together, these 
results indicate that EBP acts as an adaptor module in the EEN-EBP-Sos2 complex and that it 
cooperates with EEN to inhibit the Ras-stimulating activity of Sos2. In this context, EBP and 
EEN could be viewed to possess tumor suppressor properties in the negative feedback control 
of Ras-mediated signaling and cellular transformation.  
  
 To investigate the potential effect of MLL-EEN fusion on this trimeric complex, we 
also demonstrated that MLL-EEN oncoprotein displayed punctate nuclear localization pattern 
(Figure 8), which accords with several studies showing that the N terminus of MLL is 
responsible for targeting fusion protein into the nucleus where it exerts its oncogenic 
potential31.  Interestingly, EBP is relocated from cytoplasm into the nucleus, and displayed 
similar punctate nuclear localization pattern by MLL-EEN oncoprotein.  These results 
strongly indicate that MLL-EEN fusion not only has a dosage but also a dominant negative 
effect on the native EEN and EBP proteins which inhibit Sos2 and Ras signaling.  We 
speculate that this subversion of the tumor-suppressing activities of EEN and EBP could 
contribute to constitutive Ras activation and cellular transformation.   
 
 There is growing evidence that interaction of the Ras signaling pathway may be a 
common biological phenomenon for several MLL fusion partners. Notably, both Sos1 and 
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Sos2 were also identified as the binding partners for Abl interactor 1 (Abi-1), another MLL 
cytoplasmic fusion partner that shares structural similarity with EEN has an SH3 domain at 
the C terminus41.   E3b1/Abi-1 was originally isolated as the binding protein of Eps8, an SH3 
domain containing protein that plays a role in mitogenic signaling42,43.  Abi-1 and Sos-1 form 
a trimeric complex with Eps8 that mediates transduction of signals from Ras to Rac44, and is 
required for the inhibition of growth factor- and v-Abl-mediated activation of Erk45. MLL 
fusion proteins including the AF4 family and AF6 are also involved in Ras signaling46-48 and 
N-ras and K-ras mutation have been reported for leukemia patients with MLL translocation 
other than MLL-EEN or MLL-Abi-149,50. 
 
 The pathological significance of the Ras-mediated pathways in MLL leukemogenesis 
is further strengthened by the identification of EEN SH3 domain as a minimal transformation 
domain required for MLL-EEN mediated myeloid transformation (So et al., unpublished 
data). Although gain of function on MLL-dependent pathways is likely the most critical 
primary or initiating event among the multiple events for MLL fusion mediated 
leukemogenesis, we present evidence to suggest that deregulation of Ras-signaling pathways 
by either MLL fusion proteins or cooperative secondary mutations might represent one of the 
key secondary events required for expression of the full leukemic phenotype.    
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Figure legends 
 
Figure 1.  Structure and tissue expression of EBP.  (A) Schematic representation of EBP.  
EBP encodes a protein of 767 amino acids and comprises a central proline rich region (PRR) 
followed by four SH3 domains.  The SH3 domains are indicated by black boxes and the PRR 
is shown as hatched box.  Clone #30 and #46 were obtained from yeast two-hybrid library 
screening.  Reported sequence DKFZp434D0215 (GI: 27477709) that shows nucleotide 
sequence identity with EBP is aligned for comparison.  (B) Deduced amino acid sequence of 
EBP.  The PRR within amino acids 320-350 is bold.  Putative EEN-binding motif, PPERP in 
amino acids 343-347 is marked by asterisks.  Four SH3 domains located in amino acids 473-
529, 552-606, 639-696 and 708-765 are underlined.  (C) Tissue expression of EBP.  Analysis 
of EBP expression by PCR in multiple human adult (1-8) and fetal (9-16) tissue cDNAs.  
Arrowheads indicate specific PCR products amplified.  PCR of actin is included as control.  
Heart (1, 9); brain (2, 10); placenta (3); lung (4, 11); liver (5, 12); skeletal muscle (6, 13); 
kidney (7, 14); pancreas (8); spleen (15); thymus (16); water (17); EBP plasmid DNA (18); 
100-bp ladder marker (M). 
 
Figure 2.  EEN SH3 domain mediates interaction with EBP.  (A) Schematic 
representation of deletion mutants of EEN used in the yeast two-hybrid transformation assay.  
The hatched box indicates the central coiled coil domain (CC) and the black box denotes the 
SH3 domain.  FL and N represent the full-length and N terminus of EEN respectively.  (B) 
Yeast two-hybrid transformation assay.  Deletion mutants of EEN fused to Gal4-BD in 
pAS2-1plasmid were co-transformed with clone #30 fused to Gal4-AD in pGADGH plasmid 
into yeast strain SFY526.  Colony lift filter assay was then performed on the co-transformants.  
Positive interaction is indicated by + and no interaction is represented by −.  (C) Colony lift 
filter assay.  Positive X-gal staining was observed in co-transformants expressing FL/clone 
#30, and SH3/clone #30, but not in negative controls, FL/pGADGH and pAS2-1/clone#30.  
(D) GST pull-down assay.  HeLa cells total cell lysate expressing Myc-tagged EBP was 
incubated with either GST or GST-SH3 (SH3 domain of EEN) immobilized on glutathione 
beads, and the bound proteins were detected with anti-Myc antibody.  TCL, 10% of total cell 
lysate used in the assay. 
 
Figure 3.  Differential interaction of EBP with EEN family members.  (A) Yeast 
transformation assay of EBP with EEN family members.  Clone #30 in Gal4-AD plasmid was 
co-transformed with each EEN family member, EEN, B1 and B2 cloned in Gal4-BD plasmid 
into yeast strain SFY526.  Positive interaction accessed by colony lift filter assay is indicated 
by +.  (B) Quantitative liquid culture assay.  Lysates of cotransformants were quantified with 
ONPG substrate.  Each data point represents the average ± SD of three independent 
experiments.  (C) Amino acids alignment of the SH3 domains of EEN family members.  
Identical residues are indicated by dashes and consensus residues among family are marked 
by asterisks. 
 
Figure 4.  Proline rich motif of EBP is responsible for binding with EEN SH3 domain.  
(A) Yeast transformation assay of EBP with EEN.  Schematic diagram of deletion constructs 
of EBP is shown.  The PRR and SH3 domains are represented by hatched and black boxes 
respectively.  The arrowheads locate the putative proline rich binding motifs, PPERP within 
amino acids 343-347, and PPRPKP within amino acids 400-405.  Deletion mutants of EBP 
cloned in Gal4-AD plasmid were each co-transformed with EEN Gal4-BD plasmid into yeast 
strain SFY526.  Positive interaction accessed by colony lift filter assay is indicated by +.  (B) 
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GST pull down assay.  Extract of HeLa cells expressing Myc-tagged EEN was incubated 
with GST, GST-EBP272-358 or GST-EBP348-419 immobilized on glutathione beads.  
Binding protein was detected with anti-Myc antibody.  (C) Interaction of EBP with EEN in 
vivo.  Lysates of HeLa cells transfected with Myc-tagged EBP1-767 or EBP76-767 and/or 
FLAG-tagged EEN or SH3 domain deletion mutant, EENUSH3 FLAG were subjected to 
immunoprecipitation (IP) with anti-FLAG antibody followed by anti-Myc immunoblotting 
(WB).  TCL was immunoblotted with anti-Myc antibody. The positions of immunoblotted 
proteins are indicated by arrowheads.  The nonspecific immunoglobulin heavy chain is 
marked by an arrow. 
 
Figure 5.  Expression of EEN and MLL-EEN relocate EBP.  (A, B, C) Subcellular 
localization of Myc-tagged EBP 1-767, EBP 1-358, and EBP 532-767.  (D) EEN and EBP 
co-localize in the cytoplasm.  (E) NLSEEN interacts and recruits EBP from the cytoplasm 
into the nucleus.  (F) NLSEENUSH3 mutant unable to relocate EBP into the nucleus.  (G) 
MLL-EEN partially relocates EBP into the nucleus.  HeLa cells were transiently transfected 
with Myc-tagged EBP with FLAG-tagged EEN or MLL-EEN.  EBP and EEN/MLL-EEN 
were visualized by anti-Myc and anti-FLAG antibodies, followed by FITC-conjugated anti-
rabbit and rhodamine-conjugated anti-mouse antibodies respectively.  Nucleus in each case 
was visualized by Dapi staining.  Overlaid of Dapi-, FITC- and rhodamine-stained images are 
shown in the last column.  
 
Figure 6.  EBP interacts with EEN and Sos2 simultaneously.  (A) Yeast transformation 
assay of EBP with Sos2.  Schematic diagram of deletion constructs of EBP is presented.  
Deletion mutants of EBP cloned in Gal4-BD plasmid were each co-transformed with Sos2 
Gal4 DNA-AD into yeast strain SFY526.  Positive interaction accessed by colony lift filter 
assay is indicated by +.  (B) GST pull down assay.  Extract of HeLa cells expressing Myc-
tagged Sos2-C was incubated with GST or GST-EBP SH3 domains (SH3 A-B, B-C or C-D) 
immobilized on glutathione beads.  Binding protein was detected with anti-Myc antibody.  (C) 
Quantitative assay for EBP-EEN interaction.  Transformants of Gal4-BD and Gal4-AD 
fusion pairs were assayed using ONPG substrate.  Relative β-galactosidase activity was 
expressed as arbitrary units.  (D) Simultaneous interaction of EBP with Sos2 and EEN in vivo.  
Lysates of HeLa cells transfected with Myc-tagged EBP and/or Sos2-C were incubated with 
GST-EENSH3 fusion protein immobilized on glutathione beads.  Bound proteins were 
detected by anti-Myc antibody. 
 
Figure 7.  EBP and EEN inhibit the transformation potential of Ras and Ras-mediated 
activation of Elk-1.  (A, B) Colony formation in soft agar assay.  R6 cells (1 × 104) stably 
transfected with empty vector, RasQ61L, RasQ61L+EBP-Myc, RasQ61L+EEN-FLAG and 
RasQ61L+EBP-Myc+EEN-FLAG were suspended in 0.4% agar and overlaid in 1% bottom 
agar.  Representative colonies were photographed (A) and number of colonies was scored 
after 12 days (C).  (B) Expression of exogenous EBP-Myc and EEN-FLAG in stably 
transfected R6 cells was confirmed by Western blot analysis.  (D) EBP and EEP inhibit Ras-
mediated activation of Elk-1.  HeLa cells were transiently transfected with combinations of 
expression vectors shown.  (E)  NLSEEN and EBP lack inhibitory effect on Ras-mediated 
activation of Elk-1.  (F) Dosage dependent inhibition of EBP and EEN on the Elk-1 
transactivation by Ras.  For all the reporter assays, total amount of expression vectors was 
equalized with the empty vector, and transfection efficiency was normalized by a positive 
control, pRL-SV40.  At 48 h after transfection, luciferase activity was determined and 
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normalized with the Renilla luciferase activity.  Data shown represents means and error bar 
indicates standard deviation of three independent experiments. 
 
 
